Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 AntibodiesBenzinga • 05/25/21
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19Business Wire • 05/25/21
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ASCO 2021 HighlightsBusiness Wire • 05/25/21
Bristol Myers' (BMY) Opdivo-Yervoy Combo Gets Positive CHMP OpinionZacks Investment Research • 05/24/21
Bristol Myers Wins Positive Opinion From EU For Opdivo/Yervoy Combo In Colorectal CancerBenzinga • 05/24/21
Bristol Myers Squibb Presents New Data at Digestive Disease Week® on Zeposia (ozanimod) Highlighting Clinical Benefits and Safety Profile in Patients with Ulcerative ColitisBusiness Wire • 05/23/21
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior ChemotherapyBusiness Wire • 05/21/21
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant ChemoradiotherapyBusiness Wire • 05/20/21
Bristol Myers' Relatlimab/Opdivo Combo Therapy Tops Opdivo Alone in Untreated Melanoma PatientsBenzinga • 05/20/21
Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of DirectorsBusiness Wire • 05/20/21
Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%Business Wire • 05/19/21
Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA TrialBusiness Wire • 05/19/21
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio's Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple MyelomaBusiness Wire • 05/19/21
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced MelanomaBusiness Wire • 05/19/21
Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable MelanomaBusiness Wire • 05/19/21
Exscientia, Bristol Myers Expand AI Based Drug Discovery Collaboration With Potential Milestones Over $1.2BBenzinga • 05/19/21
